Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove

Medicine

Revealing Subtle Changes in Cardiac Function using Transthoracic Dobutamine Stress Echocardiography in Mice

doi: 10.3791/62019 Published: February 13, 2021
Stephan Settelmeier1, Tienush Rassaf1, Ulrike B. Hendgen-Cotta1

Abstract

Left ventricular (LV) dysfunction paves the final pathway for a multitude of cardiac disorders. With the non-invasive high-frequency transthoracic dobutamine stress echocardiography in humans, a reductionist investigation approach to unmask subtle changes in cardiac function has become possible. Here, we provide a protocol for using this technique in mice to facilitate expanded analysis of LV architecture and function in physiology and pathology enabling the observation of alterations in models of cardiac disease hidden in unstressed hearts. This investigation can be performed in one and the same animal and allows both, basal and pharmacologically stress-induced measurements. We outline detailed criteria for appropriate anesthesia, imaging-based LV analysis, consideration of intra- and interobserver variability, and obtaining positive inotrope response that can be attained in mice after intraperitoneal injection of dobutamine under near physiological conditions. To recapitulate the characteristics of human physiology and disease in small animal models, we highlight critical pitfalls in evaluation, e.g., a pronounced Bowditch effect in mice. To further meet translational objectives, we compare stress-induced effects in humans and mice. When used in translational studies, attention must be paid to physiological differences between mice and human. Experimental rigor dictates that some parameters assessed in patients can only be used with caution due to restrictions in spatial and temporal resolution in mouse models.

Introduction

The hallmark of many cardiac diseases in human is a systolic and/or diastolic functional impairment of the left ventricle (LV). For the detection of structural abnormalities, the diagnosis, and the management of systolic heart failure as well as the evaluation of diastolic function in patients with symptoms of heart failure, echocardiography is used as a fundamental assessment modality.

Since the symptoms are unspecific and more than one third of patients with the clinical syndrome of heart failure may not suffer from the actual heart failure, it is important to find an objective echocardiographic correlate for the patient's clinical presentation1. Furthermore, some symptoms which are occult in the resting or static state may occur under conditions of activity or stress. In patients with coronary artery disease, already minor changes in coronary perfusion can lead to regional wall motion abnormalities. However, these subtle changes cannot be evaluated using conventional echocardiography as alterations of cardiac disease can be hidden in unstressed hearts. To gain a deeper understanding of the cardiac physiopathology, stress echocardiography provides a dynamic evaluation of myocardial structure and function under conditions of exercise or pharmacological induced stress, permitting matching symptoms with cardiac findings2. Also, in small animals, this method represents a non-invasive reliable in-vivo tool3,4,5. In-line with humans, stress reaction of the myocardium can be induced via pharmacological agents in mice and rats. Dobutamine is a frequently used drug and dobutamine stress echocardiography is widely performed in humans6,7 but only sometimes used in small animal models to assess cardiac stress reaction8,9,10,11. Dobutamine is a synthetical catecholamine with a predominantly β1-agonistic effect resulting in positive inotropy and chronotropy of the heart. To achieve a correct translation from human to mouse, the technology and the conceptual framework of echocardiography, technical limitations related to e.g., the small size and rapid heart rate in the mouse must be considered. The human target heart rate in dobutamine stress echocardiography is [(220-age) x 0.85] resulting in an average heart rate increase of about 150 ± 10% in healthy volunteers12,13. For mice, such a formula is missing. The ejection fraction (EF) is described to be increased by stress echocardiography in humans by 5-20%12,14. The EF in mice is, depending on the heart rate, reported between 58 ± 11% (< 450 bpm) and 71 ± 11% (≥ 450 bpm) and changes by nearly 20% with higher heart rates4. The main mechanism in mice to increase the cardiac output is an increase in the heart rate. Partly responsible for this mechanism is the Bowditch effect or staircase phenomenon, a frequency-dependent calcium-mediated positive-inotropic cardiac response, that is more pronounced in mice than in humans15,16. In addition, (stress) echocardiography underlies intra- and interobserver variability. Therefore, a highly standardized procedure is indispensable17,18.

Here we present the detailed procedure of dobutamine stress echocardiography to acquire standardized images to unravel subtle changes in cardiac function in mice in models of health and disease. Key components include adequate anesthesia, adequate heart rate monitoring and possible pitfalls in stress-induced imaging in mice. Key parameters are the evaluation of systolic and diastolic function including consideration of the LVEF. Because mice are resistant to afterload-induced cardiac dysfunction17, this protocol may add valuable information for the use in models of valvular heart disease as well.

Subscription Required. Please recommend JoVE to your librarian.

Protocol

All methods and procedures were performed in accordance and compliance with all relevant regulations ('European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes' (Directive 2010/63/EU) and animal care was in accordance with institutional guidelines. Data from human subjects were analyzed in compliance with all institutional, national, and international guidelines for human welfare and was approved by the Local Ethics Committee (20-9218-BO). All experiments have been performed with male C57BL/6JRj at the age of 12 weeks.

1. Preparation of materials and equipment

NOTE: Figure 1 shows an example of a small-animal ultrasound workplace.

  1. Make sure to operate in a silent controlled environment with dimmable light.
  2. Pre-heat the ultrasound gel, e.g., using a gel warmer. Allow the gel to warm to 37 °C. This may take a while.
  3. Clean all instruments including the platform with a disinfectant wipe.
  4. Turn on and pre-heat the platform to 37 °C.
  5. Turn on the ultrasound machine. Enter the animal ID and protocol ID as well as other relevant information. Use a high-frequency ultrasound transducer with a center transmit of 30 MHz for mice with approximately 30 g body weight.
  6. Make sure to work with an active gas exhaustion system.
    NOTE: If using an activated charcoal filter for adsorbing the isoflurane in the exhaled flow, make sure to check the weight and replace the filter once the indicated maximal weight increase is reached.
  7. If necessary, fill the vaporizer with the adequate amount of isoflurane.
    CAUTION: Do not inhale volatile anesthetics.
  8. Prepare a dobutamine working solution of 2.5 µg/µL either by dilution of a ready-to-use injection solution or by dissolving dobutamine hydrochloride powder in 0.9% saline according to the manufacturer's instruction. The solution is stable at least for 24 h when stored at room temperature.

Figure 1
Figure 1: Small-animal cardiac ultrasound workplace. An ergonomic setting is indispensable for small-animal stress echocardiography as examination times must remain short. The workplace consists of an ultrasound machine, a small-animal anesthesia system with oxygen supply and active gas exhaust, a heated echocardiography platform with embedded ECG and movement capabilities via micromanipulators as part of an integrated rail system as well as a physiological monitoring unit. A gel warmer to warm ultrasound gel and a heat lamp are useful aids. Please click here to view a larger version of this figure.

2. Preparation of the mouse for imaging and induction of anesthesia

  1. Fill the induction chamber with 3%-4% v/v isoflurane in an oxygen-enriched gas mixture (with 1 L/min 100% O2).
  2. Weigh the mouse. Gently pick up the mouse by the tail and transfer it to the induction chamber. Ensure that the animal is sedated within a few seconds by closely observing the animal's movements.
  3. If necessary, change the gas flow to the nose cone connected to the anesthesia system (1.0-1.5 vol% isoflurane with 1 L/min 100 % O2 to maintain a stable sedation). Remove the mouse from the induction chamber and place it carefully on the pre-heated platform. Ensure that the paws lie on the ECG sensors embedded in the platform.
  4. To prevent drying of the sclera, apply ointment gel to both eyes.
    NOTE: Stress measurements will take their time.
  5. Apply a very small amount of electrode cream to the ECG sensors. Gently secure the animal with adhesive tape on all four limbs. Use a small part of adhesive tape to secure the animal's head position in the nose cone. The ECG is used to record the heart rate during image acquisition. Adjust the physiological imaging system for a stable and clear ECG signal.
    NOTE: Too much electrode cream may result in bad ECG signal quality.
  6. To protect the animal from stress during the procedure, check the adequate depth of sedation by maintaining the heart rate range at 400-450 bpm. The heart rate is obtained by the ECG. A variation of 50 bpm within the range is acceptable.
    NOTE: Movements of the animal may indicate a too narrow level of sedation. The anesthesia must not lead to cardio-depression of the mouse. The sedation can be adjusted to obtain the above-mentioned target heart rate.
  7. Using lubrication, gently insert a rectal thermometer for continuous monitoring of the body temperature. Keep the temperature in the physiological range (normally between 36.5 °C and 37.5 °C depending on the mouse strain and experimental setup). In a non-environmentally controlled animal cardiac ultrasound laboratory, the use of infrared lighting may be considered.
  8. Use chemical depilatory cream to remove the body hair from the chest. Use a clean damp paper towel to wipe clean the chest. Make sure to remove all remaining cream components (Figure 2A).
    NOTE: An electric clipper can be used before depilatory application as well. The animal is now prepared for imaging. As it is critical to keep imaging time short, the whole preparation before imaging should take less than 3 min.

Figure 2
Figure 2: Animal and transducer positioning. (A) The mouse is attached to the heated platform with all four limbs fixed on the silver ECG electrodes. A rectal thermometer is inserted for body temperature measurement. The snout is gently inserted to the nose cone of the anesthesia system. (B) Probe orientation for parasternal long axis view (PSLAX); see step 3.2. (C) Probe orientation for parasternal short axis view (PSSAX); see step 3.3. (D) Probe orientation for apical four chamber view (4CH); see step 3.4. Please click here to view a larger version of this figure.

3. Basic cardiovascular imaging

NOTE: Images can be acquired using two basic transducer positions (parasternal and apical ultrasound window) (Figure 2) and at least three ultrasound modalities (B(rightness)-mode, M(otion)-mode and Doppler-mode (color doppler and pulsed-wave (PW) doppler) (Figure 3,Figure 4,Figure 5). For basics of imaging please refer to previously published articles16,18. It is critical to obtain clear images for the comparison with later acquired stress images.

  1. Apply pre-heated ultrasound gel bubble-free to the chest.
    NOTE: Non-heated ultrasound gel will result in rapid body temperature loss which will affect the heart rate.
  2. Perform parasternal long axis (PSLAX) view.
    NOTE: PSLAX is performed to visualize the LV in its long axis. With this, e.g., the aortic root dimensions and proximal aorta dimension as well as the LV length can be obtained.
    1. With the head facing away from the investigator, tilt the table approximately 10-20° to the left and 5-10° to the front to bring the heart as anterior as possible. Place the transducer parasternally in line with the long axis of the heart with the marker (notch) pointing towards the animal's right shoulder (Figure 2B).
    2. Use micromanipulators to adjust the optimal view. Use image control panel controls to optimize the image. Acquire at least one 2D B-mode picture and one M-mode picture in midventricular level.
    3. Acquire any additional images if need for the specific question. Acquire at least 100 frames and at least 3(-6) full cardiac cycles.
  3. Perform parasternal short axis (PSSAX) view.
    NOTE: PSSAX is performed to visualize the LV in its short axis. From this view, e.g., left-ventricular end-systolic volume (LVESV), left-ventricular end-diastolic volume (LVEDV), stroke volume (SV) and cardiac output (CO) can be calculated.
    1. Rotate the transducer 90° clockwise without changing of the angulation (marker now pointing towards the animal's left shoulder) (Figure 2C). Acquire at least one B-mode image in the basal, midventricular (level of the papillary muscles), and apical view.
    2. To define the most basal and the most apical view, scroll along the long axis to the most distant points, where the full cardiac cycle of the LV chamber is still visible. Take images on the midventricular level approximately in an intermediate position at the level of the papillary muscles.
    3. Acquire at least one M-mode image in the midventricular view.
      NOTE: Some ultrasound machines provide presets for the different views; it is recommended to check for the adequate preset before acquiring images.
  4. Perform apical four chamber (4CH) view.
    NOTE: 4CH is important because it can be primarily used to evaluate the mitral valve using PW doppler.
    1. Tilt the platform that the animal is in a modified Trendelenburg position with the head down. Angle the transducer towards the head of the mouse, the marker facing towards the animal's left side (Figure 2D).
    2. Acquire at least one B-mode image as well as color doppler and PW doppler image of the mitral- and tricuspid valve. Depending on the experimental question, apply tissue doppler in the 4CH view.
      NOTE: The easiest way to reach apical 4CH position is to tilt the table from the PSAX view and to angulate the transducer. Be careful not to apply too much pressure to the thorax as this may interfere with measurements e.g. of diastolic function.

4. Dobutamine stress imaging

NOTE: Once the target heart rate is reached, standardized views should be acquired as long as the target heart rate is stable. This typically requires more than one switch between PSLAX and PSSAX. Because the switch between PSLAX and PSSAX only requires a 90° rotation, the views can be imaged easily.

  1. Perform dobutamine stress testing in one and the same animal maintaining the same anesthesia to ensure comparability. Make sure the starting heart rate remains stable in the range of 400-450 bpm. Record the ECG readings and save it together with and on the acquired images. Make sure the ECG signal is clear. Otherwise, try to re-tape all four limbs until a clear ECG signal is displayed.
  2. Again, perform PSLAX view (B-mode and M-mode images). Save the images as "baseline" image. Be sure, to save and keep in mind the initial heart rate as well.
  3. Prefill the syringe and inject 5 µg/g body weight dobutamine intraperitoneally using a 27 G needle and 1 mL syringe. Closely watch for the heart rate. Record echocardiographic images until the target heart rate is reached and use the increase of the heart rate for later analysis. A sustainable significant dobutamine-induced heart rate increase is reached after an increase of 15-30% after about 1 min, depending on the dobutamine dose.
    NOTE: Always use single-use sterile injection needles for every animal to prevent from infections. The dobutamine susceptibility and the (sub)maximal load may vary with the mouse strain and may be dependent on the experimental setup and should be defined in pre-experiments. It is recommended adjusting the dobutamine dose to the experimental setup.
    CAUTION: Follow institutional guidelines for the use of sharp and potential infectious items. Always dispose the needle into an approved medical waste container!
  4. Once the target heart rate is reached and remains stable for approximately 30 s, acquire PSLAX B-mode and M-mode images as described in step 3.
  5. Again, rotate the transducer clockwise to obtain PSSAX view as described in step 3. Here, acquire B-mode images of the basal, midventricular (level of papillary muscles) and apical level and M-mode images of the midventricular (level of the papillary muscles) level. Reassure, that the target heart rate remains stable. Otherwise, switch back to PSLAX position and start imaging again.
    NOTE: As the heart rate will drop without continuous infusion of dobutamine12 (not covered in this article), the images should be acquired within two minutes. PSLAX and PSSAX images are essential for most of the relevant stress-induced measurements (see "Representative Results" section).
  6. Now, perform apical 4CH view again (as explained in step 3.4.). Using PW doppler, measure the flow patterns of interest (as explained in step 3.4.2.). Under unstressed conditions, two characteristic waves are measured using PW doppler, one representing the passive filling of the ventricle (E(arly) wave) and one representing the active filling after atrial contraction (A(trial) wave). With increasing heart rates, these waves tend to fuse and may not be measurable distinctively under dobutamine induced stress.

5. Final steps

  1. After approximately 5 min when the heart rate will start to decrease again, make sure all views are captured.
  2. Gently remove the ultrasound gel from the chest using a clean damp paper towel. Carefully remove the tape fixation. Pay special attention to the tape fixing the animal's head to avoid pulling out the whiskers.
  3. Turn off the anesthesia. If using an active gas exhaust, make sure to continue gas exhaustion. Place the animal on a paper towel in a separated heated cage during the wake-up period. Observe the animal closely. It must not be left unattended until it has regained sufficient consciousness to maintain sternal recumbency. Once awake and fully recovered, transfer the animal to its cage.
    ​NOTE: Due to the non-final character of this technique, the animal may stay within the experiment in accordance with all relevant regulations.

6. Offline evaluation

  1. Transfer the image data to the offline analysis software on a working-station to perform detailed evaluation of the cardiac function. Pay special attention to the difference between unstressed and stressed heart function. The heart rate should always be recorded and presented.
    NOTE: Because software analysis varies between different software, it is not covered in this protocol. Please refer to the manufacturer's instructions.

Subscription Required. Please recommend JoVE to your librarian.

Representative Results

A physiological unstressed echocardiographic image acquired in PSLAX is shown in Figure 3. In diastole, the ventricle walls appear uniformly (Figure 3A) and thicken to a certain degree (Figure 3B,C). The injection of 5 µg/g body weight dobutamine i.p. leads to a significant increase of the heart rate (positive chronotropic effect)12 and the LVEF (positive inotropic effect) (Figure 3, Figure 6). The positive inotropic effect is visualized in Figure 3D-F with a thickening of the LV anterior wall in diastole (LVAWd) and even more pronounced in systole (LVAWs) and the LV posterior wall in diastole and systole (LVPWd; LVPWs) (Figure 3D,E). The effect could lead to a "kissing walls" phenomenon (Figure 3F) where the LV inner diameter (LVIDs) shortens in such an extent that the anterior and posterior walls seem to touch themselves (Figure 3E). The LVEF can be measured planimetrically in PSLAX B-mode (Figure 3A,B,D,E).

In PSSAX, the septal wall (LVSW) and lateral wall (LVLW) are visualized in addition to the LVAW and the LVPW (Figure 4). In the stressed heart, the ventricle contracts circumferential uniformly towards its center (Figure 4D,E). The "kissing walls" phenomenon can be seen in PSSAX M-mode as well (Figure 4F).

The PW doppler recording of the mitral valve flow profile shows the early diastolic velocity (E wave) and the late diastolic atrial contraction (A wave) with a distinct separation of E and A wave (Figure 5A). The isovolumetric relaxation time (IVRT) is needed for evaluation of the diastolic function and the isovolumetric contraction time (IVCT) represents the systolic function. In a healthy stressed heart, both parameters decrease significantly (Figure 6C,D). Figure 5B shows nearly fused E and A waves which can be seen with increasing heart rates. Please note that due to the significant decrease of the LVID in systole, outflow tract signals can be seen when measuring the mitral valve flow (Figure 5B).

Using specialized software, the speckle-tracking assessment of the strain and strain rate of the LV myocardium is possible in unstressed and stressed hearts (Figure 7, Figure 8) to measure early or sub-clinical chances in intrinsic myocardial contractile properties. It is important to perform calculations with the precisely recognized parts of the contraction cycle. Strain reflects the deformation of an object normalized to its original shape and size4 which equals the length of the myocardial fiber normalized to its original length6, strain rate represents the myocardial deformation rate. Strain can be measured in the radial, circumferential and longitudinal axes. One example is the measurement of the radial strain in PSSAX, which describes the increase of the myocardial wall thickness during the cardiac cycle and represents its deformation towards the center of the left ventricle19. The cardiac systolic synchrony is a measure of the systolic function of six LV segments (Figure 9E)20,21. In humans, the clinically used global longitudinal strain (GLS) is an accepted overall marker for evaluation of the systolic function.

In stress echocardiography in mice, we observed an increase in GLS (measured in PSLAX) to less negative values and a decrease in global circumferential strain (GCS) (measured in PSSAX) to more negative values (Figure 9A,B). Dobutamine administration reduced the global time to peak strain (Figure 9C) which is represented in a reduced time to peak strain across all six segments (Figure 9D). It furthermore led to a uniformly increase in radial strain rate over all segments (Figure 9F).

The results of dobutamine administration vary between species, which is important for translational approaches. Once, (sub)maximal load is reached, mice showed an average heart rate increase of +33% while humans showed an average heart rate increase of +144 % (Figure 10A). At (sub)maximal load, mice showed an average dobutamine-induced EF increase of +61 %, humans showed an average EF increase of +14% (Figure 10B).

Figure 3
Figure 3: Representative results of images acquired in parasternal long axis (PSLAX) in the unstressed and stressed animal. (A) PSLAX in diastole (unstressed). Visible are the left ventricular anterior wall (LVAWd), left ventricular posterior wall (LVPWd), the LV cavity and the aortic valve (Ao). (B) PSLAX in systole (unstressed). Visible are the left ventricular anterior wall (LVAWs), left ventricular posterior wall (LVPWs), the LV cavity and the Ao. (C) M-mode image (unstressed) of midventricular PSLAX. Visible are LVAWd; inner ventricular diameter in diastole (LVIVDd), LVPWd, LVAWs, LVIVDs, LVPWs. Heart rate of unstressed images: 425 bpm. (D) PSLAX in diastole (stressed). Visible are the LVAWd, LVPWd, the LV cavity and the Ao. (E) PSLAX in systole (stressed). Visible are LVAWs, LVPWs, the LV cavity and the Ao. (F) M-mode image (stressed) of midventricular PSLAX. Visible are LVAWd, LVIVDd, LVPWd, LVAWs, LVIVDs, LVPWs. Heart rate of stressed images: 545 bpm. Please click here to view a larger version of this figure.

Figure 4
Figure 4: Representative results of images acquired in parasternal short axis (PSSAX) in the unstressed and stressed animal. (A) PSSAX in diastole (unstressed). Visible are the left ventricular anterior wall (LVAWd), left ventricular posterior wall (LVPWd), the left ventricular inner diameter (LVIDd; arrows), the left ventricular septal wall (LVSWd) and the left ventricular later wall (LVLWd). (B) PSSAX in systole (unstressed). Visible are the left ventricular anterior wall (LVAWs), left ventricular posterior wall (LVPWs), the left ventricular inner diameter (LVIDs; arrows), the left ventricular septal wall (LVSWs) and the left ventricular lateral wall (LVLWs). (C) M-mode image (unstressed) of midventricular PSSAX. Visible are LVAWd, LVIVDd (arrows), LVPWd, LVAWs, LVIVDs (arrows), LVPWs. Heart rate of unstressed images: 400 bpm. (D) PSSAX in diastole (stressed). Visible are the LVAWd, LVPWd, LVIDd (arrows), LVSWd and the LVLWd. (E) PSSAX in systole (stressed). Visible are the LVAWs, LVPWs, LVIDs (arrows), LVSWs and the LVLWs. (F) M-mode image (stressed) of midventricular PSLAX. Visible are LVAWd, LVIVDs, LVPWd, LVAWs, LVIVDs, LVPWs. Heart rate of stressed images: 550 bpm. Please click here to view a larger version of this figure.

Figure 5
Figure 5: Representative results of images acquired in apical four chamber view (4CH) in the unstressed and stressed animal: MV flow. (A) Pulsed wave doppler of mitral valve inflow (unstressed). The E/A ratio can be derived from the E(arly) diastolic ventricle filling and the A(trial) diastolic contraction. Isovolumetric relaxation time (IVRT) serves as a marker for the diastolic function whereas isovolumetric contraction time (IVCT) represents the systole. To visualize IVRT and IVCT adequately, lower the wall filter of the ultrasound machine when acquiring the images. Heart rate of the unstressed image: 400 bpm. (B) Pulsed wave doppler of mitral valve inflow (stressed). With increasing heart rates, E and A wave approximate in height and furthermore tend to fuse. When acquiring dobutamine-induced stress echocardiography, outflow signals (*) may become visible due to the stress-induced decrease in left ventricular cavity size. Heart rate of stressed image: 560 bpm. Please click here to view a larger version of this figure.

Figure 6
Figure 6: Changes in cardiac functional parameters in dobutamine-induced stress echocardiography. (A) Increase of the heart rate in beats per minute (bpm). (B) Increase of left ventricular ejection fraction. (C) Shortening of isovolumetric relaxation time (IVRT). (D) Shortening of isovolumetric contraction time (IVCT). All: n = 3, mean ± SD, * = p < 0.05, student's t-test. Please click here to view a larger version of this figure.

Figure 7
Figure 7: Strain analysis of images acquired in parasternal long axis view (PSLAX) in unstressed and stressed animals. (A,B) Using strain analysis software, calculation of cardiac functional parameters including global longitudinal strain (GLS) is possible. In the healthy animal, the wall signals are uniform (red/blue pattern). Please click here to view a larger version of this figure.

Figure 8
Figure 8: Strain analysis of images acquired in parasternal short axis view (PSSAX) in unstressed and stressed animals. (A,B) Using strain analysis software, calculation of cardiac functional parameters including global circumferential strain (GCS) is possible. In the healthy animal, the wall signals are uniform (red/blue pattern). Please click here to view a larger version of this figure.

Figure 9
Figure 9: Changes in strain parameters in unstressed and stressed animals. (A) Decrease of global longitudinal strain. (B) Increase of global circumferential strain. (C) Reduced global time to peak strain. (D) Reduced time to peak strain across all six segments. (E) Schematic overview of anatomical segments in short axis view. (F) Increased radial strain rate after dobutamine administration. As values are software-dependent and referent values in mice are currently not present, the values must be seen individually for each experimental setup. The graphs represent the result of Figure 7 and Figure 8. AFW = anterior free wall; LW = lateral wall; PW = posterior wall; IFW = inferior free wall; PS = posterior septum; AS = anterior septum. Please click here to view a larger version of this figure.

Figure 10
Figure 10: Differences between mouse and human cardiac functional parameters in dobutamine-induced stress echocardiography. (A) percentual increase of heart rate. (B) percentual increase of left ventricular ejection fraction. The values derive from literature13,22 as well as clinical routine measurements. All: n = 3, mean ± SD. Please click here to view a larger version of this figure.

Subscription Required. Please recommend JoVE to your librarian.

Discussion

Stress-induced evaluation of the cardiac function is widely used in humans in a clinical setting using exercise testing or pharmacological stress testing6,7. Because immediate post-exercise echocardiography of mice is very limited due to the need for sedation, dobutamine-induced stress echocardiography is likely to be the most translational method to assess stress-induced cardiac physiopathology. Reliable information on cardiac function can be obtained using real-time pressure-volume analysis in a final approach23. Echocardiography adds a valuable insight into long-term examination and, therefore, additionally meets the requirements of the 3R principle (replace, reduce, refine).

The most common use of stress echocardiography in patients is the search for wall abnormalities and myocardial viability as well as the evaluation of valvular heart disease and their importance is indicated in recent guidelines24,25. Nevertheless, those applications are only a piece of the physiopathological puzzle of a failing heart. We, therefore, believe that the use of pharmacological stress testing in preclinical research will help to uncover hidden and subtle changes in the cardiac function in models of disease and in cardiac phenotyping.

Anesthesia and heart rate
With a few exceptions of conscious echocardiography in mice26, sedated echocardiography is the most widespread echocardiographic method in mice3,4. Although up to 1.5 vol% isoflurane will be enough for a proper sedation, isoflurane - in contrast to humans - leads to a decrease of heart rate in mice. Therefore, it is crucial to find the right balance between sedation and heart rate influence, especially when performing stress testing. Nevertheless, isoflurane causes less cardiodepression compared to other anesthetics27. The physiological heart rate of mice is >450 bpm4 and with respect to a slightly reduced heart rate due to anesthesia, we defined a target heart rate of 400-450 bpm as a suitable target heart rate of unstressed mice to obtain a significant increase in heart rate after dobutamine injection. Therefore, careful monitoring of the heart rate is indispensable as it serves as primary control mechanism of adequate anesthesia and as verification of a successful dobutamine effect when reaching the pre-defined heart rate increase after dobutamine injection. At this point, it is important to use the same heart rate corridor within one group of mice and compared to another group of mice. One should note that the effect of dobutamine is more inotropic than chronotropic.

Dobutamine administration
In mice echocardiography, dobutamine is administered i.v. or i.p. with the dose ranging from 1-5 µg/g body weight11,28,29,30. Dosing is critical, as dobutamine plasma concentrations and cardiac functional parameters correlate in a linear relationship13. We here decided for i.p. injection of 5 µg/g body weight because it showed a significant, robust, reproducible and transient increase in cardiac functional parameters reaching the (sub)maximal load in male C57BL6/6JRj mice used. Because the protocol is, unlike to human patients, not searching for interindividual differences within the experimental mice group, the same (sub)maximal load should be reached in every mouse examined requiring the same application dose in every animal. At this point we would like to point out that dose-response testing until a significant, robust, reproducible and transient increase in cardiac functional parameters is reached should be done dependent on the mice strain and the experimental setting beforehand.

I.p. injection is a feasible administrative route as i.v. injection requires higher effort in mice. Furthermore, assuming the comparable peritoneal resorption rate of dobutamine in mice, the i.p. injection approach avoids technical barriers and inaccuracies in i.v. tail vein injection, especially when serial testing is performed in longitudinal experiments, which would require several tail vein injections of previously punctured vessels. Nevertheless, similar to human procedures, an i.v. application approach could also be adapted9,27,31. Because of different pharmacodynamics and pharmacokinetics, this may require an additional dose-response testing in advance. As predominantly selective β1-adrenergic drug, dobutamine is often chosen due to its cardiac inotropic and chronotropic effects with minimal direct effect on the blood pressure in preclinical studies9. As an alternative to dobutamine, the administration of isoproterenol is possible. Isoproterenol is a non-selective β-adrenergic agonist with effects on both β1-and β2-adrenergic receptors, which - in contrast to dobutamine - causes a lowering of the mean arterial pressure after application due to vasodilatation. It leads to cardiac hypertrophy and fibrosis and is used to mimic stress-induced cardiac injury in a rather acute and as heart failure model in a rather chronic administration9,32, so that it is somewhat inferior to dobutamine when repeated stress echocardiography is planned in a longitudinal animal experiment. Nevertheless, the comparison of both substances did not show significant differences in inotropic and lusitropic effects in healthy mice33. Overall, dobutamine is more commonly used for stress testing in the clinical setting, while isoproterenol is seen in the experimental setting27,33.

Evaluation of cardiac function
Stress-induced changes can be assessed visually in B-mode and with benefits in spatiotemporal solution in M-mode, making it somewhat superior in stress imaging. In untreated healthy mice or mice without wall abnormalities like models of chemotherapeutic-induced cardiotoxicity19, M-mode images of the midventricular level acquired in PSLAX or PSSAX can be used to adequately measure LV systolic function34. However, in the presence of regional wall (motion) abnormalities, e.g. after myocardial infarction35, the planimetric measurement in B-mode images may be preferable to assess myocardial contractile reserve.

Despite excessive research, diastolic heart failure with preserved EF still is an unsolved entity of heart failure36. For deeper understanding of underlying mechanisms, the analysis of small animal models of diastolic heart failure is indespensable37. For diastolic evaluation, markers like mitral valve inflow patterns, IVRT and IVCT are well established markers4,38. In stress testing, those markers are subjected to change. Due to missing standard values in stress testing in mice, the changes must be closely compared to the non-treated control group. Our findings may serve as orienting values. While we already have increased the sensitivity to detect subtle and early changes in myocardial function by stress testing, the sensitivity can be further increased using speckle-tracking imaging as myocardial strain may detect early sub-clinical changes beforehand39. As shown in our representative results, strain-derived markers may change by stress testing, which is of interest when comparing models of cardiac diseases like myocardial infarction, where segmental analyses become important. With the current absence of reference values despite efforts for standardization of echocardiography in mice4, these effects should be reassessed for every individual experimental setting. Attention in stress testing strain analysis is needed, as the analysis of high heart rates and significantly induced cardiac function parameters depends on calculations performed with the accurately recognized parts of the contraction cycle.

Intra- and interobserver reliability
As an operator-dependent ultrasound examination, echocardiography underlies possible intra- and interobserver variability3, especially when performed in one and the same animal. A well-respected guide to assess the reproducibility of echocardiographic measurements has been established40. With emerging software techniques, automated assessment algorithms have been developed41. We here recommend a blinded image acquisition as well as blinded software-based offline image interpretation, whenever possible. To assure reproducibility especially in stress echocardiography, images with a comparable heart rate increase should be analyzed.

Between mice and human: Translational application
With all advantages and evolution of preclinical ultrasound application, there remains the question of translational limitations.

As we have shown, the effects of dobutamine vary between mice and humans. Translational preclinical researchers should not expect the same increase of cardiac functional parameters they are used to in human patients or vice versa. If, however, a comparison should be performed, we suggest only to compare the points of (sub)maximal load. A more pronounced Bowditch effect15,16 has to be kept in mind when translating preclinical echocardiographic measurements.

Furthermore, due to limitations because of small ultrasound windows, the changes after dobutamine injection in heart rate and contractility, evaluations of e.g. stress assessment of the pulmonary circulation42, cannot be performed in mice without further ado. Further research is needed to assess strain evaluation in mice. Nevertheless, dobutamine-induced stress-echocardiography is a feasible, reproduceable and valuable tool for unmasking hidden subtle changes in the preclinical research area.

The application of our protocol allows for biologically highly relevant insights into systolic and diastolic dysfunction of the heart and can besides cardiac phenotyping of different mouse strains be expanded to distinct models of chronic overload pressure, myocardial infarction, diastolic dysfunction and heart failure with preserved LVEF as well as valvular heart disease.

Subscription Required. Please recommend JoVE to your librarian.

Disclosures

The authors have nothing to disclose.

Acknowledgments

The authors acknowledge the following funding sources: German Research Foundation (UMEA Junior Clinician Scientist, Stephan Settelmeier; RA 969/12-1, Tienush Rassaf; HE 6317/2-1, Ulrike Hendgen-Cotta), Else-Kroener-Fresenius-Stiftung (2014_A216, Tienush Rassaf).

Materials

Name Company Catalog Number Comments
Activated Charcoal Filter UNO BV 180000140 http://www.unobv.com/Rest%20Gas%20Filters.html
Aquasonic 100 Ultrasound Transmission Gel Parker Laboratories 001-02 https://www.parkerlabs.com/aquasonic-100.asp
Chemical Hair removal lotion General Supply -
Cotton Swaps General Supply -
ddH2O General Supply -
Dobutamine Carinopharm 71685.00.00 https://www.carinopharm.de/stammsortiment/#103
Flowmeter for laboratory animal anesthesia UNO BV SF3 http://www.unobv.com/Flowmeters.html
Gas Exhaust Unit UNO BV - http://www.unobv.com/Gas%20Exhaust%20Unit.html
Heating Lamp Philips -
Induction Box UNO BV - http://www.unobv.com/Induction%20box.html
Medical Sharps Container BD 305626 https://legacy.bd.com/europe/safety/de/products/sharps/
MX400 ultrasound transducer (20-46 Mhz) VisualSonics MX400 https://www.visualsonics.com/product/transducers/mx-series-transducers
Octenisept disinfectant Schuelke 173711 https://www.schuelke.com/de-de/produkte/octenisept.php
Omnican F syringe with needle 1ml B. Braun 9161502S https://www.bbraun.de/de/products/b60/omnican-f.html
Paper Towels General Supply -
Signacreme Electrode Cream Parker Laboratories 017-05 https://www.parkerlabs.com/Signacreme.asp
Standard Gauze Pads BeeSana Meditrade 4852728 https://www.meditrade.de/de/wundversorgung/verbandstoffe/beesana-mullkompresse/
Thermasonic Gel Warmer Parker Laboratories 82-03-20 CE https://www.parkerlabs.com/thermasonic_apta_sbp.asp
Transpore Tape 3M 1527NP-0 https://www.3mdeutschland.de/3M/de_DE/unternehmen-de/produkte/~/3M-Transpore-Fixierpflaster/
Vaporizer Sigma Delta UNO BV - http://www.unobv.com/Vaporizers.html
Vevo 3100 high-frequency preclinical ultrasound imaging system VisualSonics Vevo3100 https://www.visualsonics.com/product/imaging-systems/vevo-3100 * required software package: Cardiovascular package; B-mode, M-mode, pulsed-wave doppler mode
Vevo Imaging Station with integrated rail system, heated platform and physiological monitoring unit VisualSonics - https://www.visualsonics.com/product/accessories/imaging-stations
VevoLab Analysis Software VisualSonics Vers. 3.2.5 https://www.visualsonics.com/product/software/vevo-lab *required software package: Vevo Strain, LV analysis

DOWNLOAD MATERIALS LIST

References

  1. Oh, J. Echocardiography in heart failure: Beyond diagnosis. European Journal of Echocardiography. 8, (1), 4-14 (2007).
  2. Lancellotti, P., et al. The clinical use of stress echocardiography in non-ischaemic heart disease: Recommendations from the european association of cardiovascular imaging and the american society of echocardiography. Journal of the American Society of Echocardiography. 30, (2), 101-138 (2017).
  3. Lindsey, M. L., Kassiri, Z., Virag, J. A. I., de Castro Bras, L. E., Scherrer-Crosbie, M. Guidelines for measuring cardiac physiology in mice. American Journal of Physiology-Heart and Circulatory Physiology. 314, (4), 733-752 (2018).
  4. Zacchigna, S., et al. Toward standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on myocardial function. Cardiovascular Research. 110 (2020).
  5. Hendgen-Cotta, U. B., et al. A novel physiological role for cardiac myoglobin in lipid metabolism. Scientific Reports. 7, 43219 (2017).
  6. Al-Lamee, R. K., et al. Dobutamine stress echocardiography ischemia as a predictor of the placebo-controlled efficacy of percutaneous coronary intervention in stable coronary artery disease: The stress echocardiography-stratified analysis of ORBITA. Circulation. 140, (24), 1971-1980 (2019).
  7. Cadeddu Dessalvi, C., Deidda, M., Farci, S., Longu, G., Mercuro, G. Early ischemia identification employing 2D speckle tracking selective layers analysis during dobutamine stress echocardiography. Echocardiography. 36, (12), 2202-2208 (2019).
  8. Li, Z., et al. Reduced myocardial reserve in young x-linked muscular dystrophy mice diagnosed by two-dimensional strain analysis combined with stress echocardiography. Journal of the American Society of Echocardiography. 30, (8), 815-827 (2017).
  9. Puhl, S. L., Weeks, K. L., Ranieri, A., Avkiran, M. Assessing structural and functional responses of murine hearts to acute and sustained beta-adrenergic stimulation in vivo. Journal of Pharmacological and Toxicological Methods. 79, 60-71 (2016).
  10. Ferferieva, V., et al. Assessment of strain and strain rate by two-dimensional speckle tracking in mice: comparison with tissue Doppler echocardiography and conductance catheter measurements. European Heart Journal Cardiovascular Imaging. 14, (8), 765-773 (2013).
  11. Wiesmann, F., et al. Dobutamine-stress magnetic resonance microimaging in mice : acute changes of cardiac geometry and function in normal and failing murine hearts. Circulation Research. 88, (6), 563-569 (2001).
  12. Pellikka, P. A., et al. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: From the American Society of Echocardiography. Journal of the American Society of Echocardiography. 33, (1), 1-41 (2020).
  13. Ahonen, J., et al. Pharmacokinetic-pharmacodynamic relationship of dobutamine and heart rate, stroke volume and cardiac output in healthy volunteers. Clinical Drug Investigation. 28, (2), 121-127 (2008).
  14. Nath Das, R. Determinants of cardiac ejection fraction for the patients with dobutamine stress echocardiography. Epidemiology. 07, (03), (2017).
  15. Balcazar, D., et al. SERCA is critical to control the Bowditch effect in the heart. Scientific Reports. 8, (1), 12447 (2018).
  16. Zhang, B., Davis, J. P., Ziolo, M. T. Cardiac catheterization in mice to measure the pressure volume relationship: Investigating the Bowditch Effect. Journal of Visualized Experiments. (100), e52618 (2015).
  17. Casaclang-Verzosa, G., Enriquez-Sarano, M., Villaraga, H. R., Miller, J. D. Echocardiographic approaches and protocols for comprehensive phenotypic characterization of valvular heart disease in mice. Journal of Visualized Experiments. (120), e54110 (2017).
  18. Respress, J. L., Wehrens, X. H. Transthoracic echocardiography in mice. Journal of Visualized Experiments. (39), e1738 (2010).
  19. Rea, D., et al. Strain analysis in the assessment of a mouse model of cardiotoxicity due to chemotherapy: Sample for preclinical research. In Vivo. 30, (3), 279-290 (2016).
  20. Beyhoff, N., et al. Application of speckle-tracking echocardiography in an experimental model of isolated subendocardial damage. Journal of the American Society of Echocardiography. 30, (12), 1239-1250 (2017).
  21. Pappritz, K., et al. Speckle-tracking echocardiography combined with imaging mass spectrometry assesses region-dependent alterations. Scientific Reports. 10, (1), 3629 (2020).
  22. Krahwinkel, W., et al. Dobutamine stress echocardiography. European Heart Journal. 18, suppl_D 9-15 (1997).
  23. Michel, L., et al. Real-time pressure-volume analysis of acute myocardial infarction in mice. Journal of Visualized Experiments. (137), e57621 (2018).
  24. Baumgartner, H., et al. ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 38, (36), 2739-2791 (2017).
  25. Knuuti, J., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 41, (3), 407-477 (2020).
  26. Schoensiegel, F., et al. High throughput echocardiography in conscious mice: Training and primary screens. European Journal of Ultrasound. 32, Suppl 1 124-129 (2011).
  27. Gao, S., Ho, D., Vatner, D. E., Vatner, S. F. Echocardiography in Mice. Current Protocols in Mouse Biology. 1, 71-83 (2011).
  28. Scherrer-Crosbie, M., Thibault, H. B. Echocardiography in translational research: of mice and men. Journal of the American Society of Echocardiography. 21, (10), 1083-1092 (2008).
  29. Tanaka, N., et al. Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation. 94, (5), 1109-1117 (1996).
  30. Roth, D. M., et al. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation. 99, (24), 3099-3102 (1999).
  31. Castle, P. E., et al. Anatomical location, sex, and age influence murine arterial circumferential cyclic strain before and during dobutamine infusion. Journal of Magnetic Resonance Imaging. 49, (1), 69-80 (2019).
  32. Ren, S., et al. Implantation of an isoproterenol mini-pump to induce heart failure in mice. Journal of Visualized Experiments. (152), e59646 (2019).
  33. Carillion, A., Biais, M., Riou, B., Amour, J. Comparison of Dobutamine with Isoproterenol in echocardiographic evaluation of cardiac β-adrenergic response in rats: 4AP8-9. European Journal of Anaesthesiology. 29, (2012).
  34. Lang, R. M., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging. 16, (3), 233-270 (2015).
  35. Lindsey, M. L., et al. Guidelines for experimental models of myocardial ischemia and infarction. American Journal of Physiology-Heart and Circulatory Physiology. 314, (4), 812-838 (2018).
  36. Pieske, B., et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 40, (40), 3297-3317 (2019).
  37. Riehle, C., Bauersachs, J. Small animal models of heart failure. Cardiovascular Research. 115, (13), 1838-1849 (2019).
  38. Rammos, C., et al. Impact of dietary nitrate on age-related diastolic dysfunction. European Journal of Heart Failure. 18, (6), 599-610 (2016).
  39. Koshizuka, R., et al. Longitudinal strain impairment as a marker of the progression of heart failure with preserved ejection fraction in a rat model. Journal of the American Society of Echocardiography. 26, (3), 316-323 (2013).
  40. Bunting, K. V., et al. A practical guide to assess the reproducibility of echocardiographic measurements. Journal of the American Society of Echocardiography. 32, (12), 1505-1515 (2019).
  41. Grune, J., et al. Accurate assessment of LV function using the first automated 2D-border detection algorithm for small animals - evaluation and application to models of LV dysfunction. Cardiovascular Ultrasound. 17, (1), 7 (2019).
  42. Lau, E. M. T., et al. Dobutamine stress echocardiography for the assessment of pressure-flow relationships of the pulmonary circulation. Chest. 146, (4), 959-966 (2014).
This article has been published
Video Coming Soon
PDF DOI DOWNLOAD MATERIALS LIST

Cite this Article

Settelmeier, S., Rassaf, T., Hendgen-Cotta, U. B. Revealing Subtle Changes in Cardiac Function using Transthoracic Dobutamine Stress Echocardiography in Mice. J. Vis. Exp. (168), e62019, doi:10.3791/62019 (2021).More

Settelmeier, S., Rassaf, T., Hendgen-Cotta, U. B. Revealing Subtle Changes in Cardiac Function using Transthoracic Dobutamine Stress Echocardiography in Mice. J. Vis. Exp. (168), e62019, doi:10.3791/62019 (2021).

Less
Copy Citation Download Citation Reprints and Permissions
View Video

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
simple hit counter